• Tonix reported Journal of Virology data showing the 2022 mpox outbreak strain (clade IIb) was up to 100,000-fold less virulent than clade IIa.
• Research identified three new murine models to study mpox infection, supporting evaluation of medical countermeasures.
• Work aligns with development of TNX-801, a live, attenuated horsepox-based vaccine candidate aimed at preventing mpox and smallpox.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150905PRIMZONEFULLFEED9762164) on July 15, 2026, and is solely responsible for the information contained therein.